Format

Send to

Choose Destination
Curr Mol Med. 2019 Oct 23. doi: 10.2174/1566524019666191023121607. [Epub ahead of print]

Relaxin and the Cardiovascular System: From Basic Science to Clinical Practice.

Author information

1
Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal
2
Cardiovascular Research Centre, Porto, Portugal
3
Internal Medicine Department, São João Hospital Centre, Porto, Portugal
4
Cardiothoracic Surgery Department, São João Hospital Centre, Porto, Portugal

Abstract

The peptide hormone relaxin was originally linked to reproductive physiology where it is believed to mediate systemic and renal hemodynamic adjustments to pregnancy. Recently, its broad range of effects in the cardiovascular system have been the focus of intensive research regarding its implications under pathological conditions and potential therapeutic potential. An understanding of the multitude of cardioprotective actions prompted the study of serelaxin, recombinant human relaxin-2, for the treatment of acute heart failure. Despite early promising results from phase II studies, recently revealed RELAX-AHF-2 outcomes were rather disappointing and the treatment for acute heart failure remains an unmet medical need. This article reviews the physiologic actions of relaxin on the cardiovascular system and its relevance in pathophysiology of cardiovascular disease. We summarize the most updated clinical data and discuss future directions of serelaxin for the treatment of acute heart failure. This should encourage additional work to determine how can relaxin's beneficial effects be exploited for the treatment of cardiovascular disease.

KEYWORDS:

Acute Heart Failure; Biomarker; Cardiovascular System; Cardiovascular drugs; Relaxin; Vasodilator

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center